biotech

biotech Articles

Durect shares dropped early on Friday after an FDA committee vote on Posimir, the company’s pain relief treatment.
Neon Therapeutics shares shot up on Thursday after the firm announced that it will be acquired by BioNTech. Are Neon Therapeutics shareholders getting enough out of the deal?
Nektar Therapeutics shares were crushed on Wednesday after the FDA did not recommend the company’s pain drug.
An FDA nod for NanoFlu, a recombinant quadrivalent seasonal influenza vaccine candidate, offered a boost to Novavax shares on Wednesday.
Aquestive Therapeutics' shares lost nearly a third on Monday after the firm received an update from the FDA concerning its seizure treatment.
Adaptimmune shares absolutely exploded on Monday after the company announced encouraging responses for its Spear T-cell platform.
The December 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks increased.
Here are 20 biotechnology and pharmaceutical stocks that have been given big analyst upside targets for 2020.
Dermira shares made a handy gain to close out the week after it was announced that Eli Lilly would be acquiring the firm.
Applied Genetic Tech shares jumped by more than 50% on Thursday after the firm announced positive interim data from its midstage trial in X-linked retinitis pigmentosa.
DBV Tech shares jumped on Thursday after the firm announced positive topline results from its late-stage study in children with a peanut allergy.
Here are 11 biotech and pharma stocks that have been given big analyst upside targets for 2020.
Xeris Pharmaceuticals shares pushed higher on Tuesday after the firm announced positive topline results from its midstage study in adults with Type 1 diabetes mellitus.
Apellis Pharmaceuticals shares jumped on Tuesday after the firm announced positive results from its late stage study in adults with paroxysmal nocturnal hemoglobinuria (PNH). Specifically, the data...
On a company by company basis, investing in biotechs is somewhat tricky. However, there is an investment strategy that makes it much easier.